At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
BMS-986263 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986263 in Adults With Advanced Hepatic Fibrosis After Virologic Cure of Hepatitis C
In Brief
A Phase 2 clinical trial evaluating BMS-986263 and Placebo for Hepatic Cirrhosis and Liver Fibrosis. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This is a study of experimental medication BMS-986263 in adult patients with advanced hepatic fibrosis (scar tissue in the liver caused by inflammation that is far on in progress) after the patient is cured of hepatitis C (an infection caused by a virus that attacks the liver and leads to inflammation).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Cirrhosis, Liver Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartFeb 2018
Primary CompletionDec 2018
Study CompletionMay 2019
TodayJul 2026
First PostedFeb 5, 2018
Enrollment StartFeb 14, 2018
Primary CompletionDec 10, 2018
Study CompletionMay 28, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.4 years ago
Interventions
BMS-986263drug
Administered by intravenous (IV) infusion
Placeboother
Administered by intravenous (IV) infusion